Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02286752

Enrollment

Registered

2014-11-10

Start date

2014-06-30

Completion date

2015-01-31

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incidence of Postoperative Nausea and Vomiting

Brief summary

Postoperative nausea and vomiting is one of most common complications after general anesthesia. Female sex, history of postoperative nausea and vomiting, motion sickness, non smoker status, opioid administration are known as risk factors for developing postoperative nausea and vomiting. It has been suggest that antagonism of residual neuromuscular block with a mixture of neostigmine and atropine at the end of the surgery increases the risk of postoperative nausea and vomiting. Sugammadex is a very safe drug with almost no serious adverse effects. The known adverse effects include slight coughing, movement, an altered taste sensation in the mouth, transient prolongation of the QT interval, hypersensitivity, and a short term prolongation of the activated partial thromboplastin time. The aim of this study was to compare the sugammadex versus neostigmine plus atropine for reversal of rocuronium induced neuromuscular blockade in terms of incidence of postoperative nausea and vomiting.

Interventions

DRUGNeostigmine

for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine

DRUGsugammadex

for reversal of neuromuscular block: sugammadex 2 mg kg-1

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status 1 and 2 * endotracheal intubation and general anesthesia scheduled for elective surgery

Exclusion criteria

* age \< 18 years, \> 65 years * pregnancy * refusal to participate and patients already participating in another study * allergy to study drugs * communication difficulty * psychiatric and neurological disorders * use of analgesics or sedative or antiemetic drugs within 24 hours before surgery. * emergency surgery * history of drug or alcohol abuse * ASA 3 and above * patients with vertigo * Laparoscopic surgery, oncologic surgery, strabismus and mid ear surgery neurosurgery, gynecologic surgery, breast surgery

Design outcomes

Primary

Measure	Time frame	Description
Verbal Descriptive Scale	within postoperative 24 hours	0: no nausea 1: mild 2: moderate 3: severe

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026